Brought to you by 
Novartis partners with Orasi for CNS biomarker
25 May 2022
Executive Summary
Orasi Medical Inc., a University of Minnesota spin-off that is developing software to improve and speed up drug development, has agreed to help Novartis Pharmaceuticals Corp. develop a CNS biomarker using the Orasi Index and magnetoencephalography (MEG) to measure disease and treatment effect.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Medical Devices
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis partners with Orasi for CNS biomarker
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice